Sara Ahnström
COO
Replay available
Apotea (Stockholm:APOTEA) Q1 2026 earnings call, held 2026-04-29. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/apotea-ab-apotea-q1-2026-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good morning, everyone, and welcome to APTEA's first quarter report this year. We will present today from our office in Stockholm, and as usual, we will start with the presentation and then move on to a Q&A with spoken questions. Today's presenters will be Per Svärdson, our CEO and co-founder, Johan Morild, our CFO, and myself, Sara Ahnström, COO. So let's begin.
0:28 Thank you. We have had a good quarter with good profitability and stable growth.
0:35 Yes, we had revenues of 1,937,000,000 and a growth of 10.5% in the quarter and an operating margin in line with last year. The operating margin was 5.2%. Yeah, and
0:55 As I said, we have had improved profitability and stable growth and our project, I think they were heading in the right direction.
1:08 And since this fall, we have put a lot of focus into our growth initiatives, as we have said before. And some of these have now been launched. We're very happy about that. Most recently, we soft-launched our site in Norway, apothea.no, which means that we are now selling our health and beauty products on the Norwegian market under the Apothea brand on the site. We are delivering the customer orders from our fulfillment center in Varberg. And this is of course a step to strengthening our position in Norway as well as increase the utilization of the new fulfillment center. We have also continued during the quarter to scale up the production in Varberg. We have sent out as much as 27,000 orders in one day.
1:57 And we have done that by increasing the number of shifts as we are now working both evenings and weekend shifts as well. And approximately one third, slightly above one third of all customer orders are now going from Varby.
2:13 And when we launched this soft launch of Norway, we also launched our new platform. And that was a big step as well.
2:22 yes and with the growth in the quarter of 10.5 percent we now have rolling 12 months revenues approaching 7 billion and 400 million and we have a rolling and just a little bit margin which is flat compared to q4 24 and it was 4.2 percent and let's take a closer look on the revenues To the left you see our net revenue development and as mentioned we had growth in the quarter of 10.5% and the growth was fairly evenly distributed across our product areas. Roughly 10% growth in Rx as well as in non-Rx and we experienced a continued solid demand for pharmaceutical products online.
3:13 To the right you see our gross margin. We had a slight increase in the gross margin in Q1 compared to Q1 25 and the increase was the result of successfully executed campaigns as well as improved purchasing. Our ambition is to have a fairly stable gross margin and with attractive prices attract more and more people to buy pharmacy products online. yes we had a strong operating profit in the quarter we had a operating profit of 101 million and the operating profit increased despite increased depreciations related to the new fulfillment center in Varberg and the increasing operating profit was driven by increased net revenues as well as a slight higher gross margin as mentioned and continued good cost control Let's talk more about the cost then. To the right you see a breakdown of our operating costs and as you can see the depreciations in percentage of revenues increased in Q1 as expected and the increase was related to the new fulfillment center in Varbergh that was opened up last year and depreciation started in Q4 last year.
4:41 If we then look on personnel costs and other operating costs and take those combined, these are fairly flat compared to a year ago and we maintain a good cost control. And as we've mentioned before and worth mentioning again, the mix between personnel costs and other operating costs is also impacted by the usage of external staffing in our fulfillment centers. We did not have any items affecting comparability in Q1. Yes, we had a strong operating cash flow in Q1 and that was fairly stable compared to a year ago. We had limited investments in Q1. The investments in Q125 were related to the new fulfillment center in Varberg, which is now the platform investments are completed and we expect this year to have significantly lower capex level compared to a year ago.
5:42 If we take a close look on the networking capital to the right, you can see that the inventory increased compared to a year ago. And the increase in inventory also impacted the inventory turnover rate somewhat, which is slightly lower. And the increase was the result in the increase in inventory was primarily the result of increased inventory in Barbary. We have A slightly lower return on capital employed in Q1 compared to a year ago, however, it remains a strong return. And the decrease in return on capital employed is the result of the new assets related to the new fulfillment center in Varberg.
6:30 And then finally, in terms of numbers, we had, let's look on the net depth and the net cash position. end of March we had a net cash position of 105 million Swedish and the increase in cash compared to a year ago was the result of the strong underlying operating cash flow as well as then in Q1 26 limited investments.
6:59 So and our focus ahead is to continue to build the pharmacy of tomorrow to improve the customer journey and improve our efficiency and I think we have like hundreds of projects to improve the customer journey to make it a little bit easier for the customer make it I mean retail is all about the customer and if we can improve the customer satisfaction and then we will both be more profitable, we will grow faster and so on. So that's our super main focus.
7:36 Yes, and we will continue to have a very strong focus on growth going forward. And as we mentioned at the beginning, we have done a soft launch of the apothea.no site, but that also means that we will continue to work on that site and continue to improve the customer offering in Norway. We will also continue to evaluate and launch several growth-related initiatives going forward still. And I think one of the examples of kind of optimizing the operations also in terms of sales-oriented initiatives that we have done is that we have also expanded our offering of refrigerated deliveries on pharmaceuticals in Sweden. And these types of initiatives we see a great potential in, I would say. We will of course also continue to scale up the production in Varberg. The automation has a capacity of 50,000 orders each day and as I mentioned in the beginning we have reached 27 as of now.
8:34 So we will continue to optimize the operations making sure that the system is stable even in higher volumes and also work with the related processes such as purchasing inventory levels and the freight options from the Varberg facility. So I think we have a we have not reached the maximum level yet.
8:54 Yeah and as all of you already know it's a lot of uncertainty out there in the world and We haven't been affected yet. We haven't seen any signs of that, but we have a big focus on it every day because it can affect us in the future, but hopefully not. I mean, like logistics, where containers are in the world and plastic bottles and so on. But we haven't seen it and we are in a very stable industry, but we have a focus on it. Thank you.
9:32 And that was the end of the presentation as well. So now we move on to the Q&A with spoken questions. The next question comes from Johan Fred from SEB. Please go ahead.
9:45 Yes, good morning, guys. Johan Fred here from SEB. A few questions on my side. Starting off with the revenue growth. Could you give us a sense of the split between volume growth and sort of price mix effect in the quarter?
10:04 I think we have a fairly stable AOV in the period.
10:15 And I think we have some price effects, but it's more like very expensive medicine. It's not like higher prices on the same product, but we sell more and more of very expensive medicines.
10:36 Okay, so mix then was an important factor in RX sales growth while sort of volume drove OTC growth, is that correct?
10:48 It's a little bit 50-50, isn't it?
10:50 I don't have the exact split, but yes, in terms of Rx, we had a positive impact from increased orders and increased share from very expensive medicines. Whereas the volume was the main driver in other segments.
11:18 And all the gross margin came in at, I believe, 28.3%, which is, I believe, the highest gross margin I think you ever reported. How much of this was driven by sort of one-off campaign timing in the quarter and how much was structural improvement in procurement?
11:38 I mean, if you compare with Q4, we have done a lot of improvements in how we buy things to two warehouses and so on. and our goal is to have a stable gross margin and it goes a little bit up and a little bit down but it's quite stable and in this particular in Q1 I mean then we have had successful campaigns I mean you buy you should buy the products from the right source at the right time in the right amount to the right warehouse and do campaigns together with the supplier and have a successful campaigns and so on so it's I mean we have done a quite good job with that and we can absolutely try to do it next quarter as well but it goes I mean it goes a little bit up and go down okay so more sort of I don't want to call the one-off effect but specifically relating to Q1
12:38 essentially the opposite of what happened in Q4, is that correct?
12:42 Yes, something like that.
12:47 In the light of this, how should we think about the revenue contribution from services? It grew 30% in Q1, I believe. Is that relating to the campaigns you are alluding to, or is there anything that could indicate that this is a higher structural base going forward?
13:09 And then we try to improve or erase that as well. But I mean, it's absolutely related to campaigns.
13:19 Okay, got it. Got it. Makes sense. A final one, then, if I may, on CapEx, which was a minuscule here in Q1. You've previously guided for around 50 to 70 million, I believe, annually going forward. Does this still hold? And if so, what types of investments should we expect in 2026 to get to that number?
13:44 We evaluate all possible investments we can do. And if we see that it's a profitable investment, we will do it. And this 50 to 70, I mean, it's more like some kind of target, but we haven't found that much investments yet because now we are improving the investments we already have done. So I think we have to come back over time and calibrate that.
14:21 I think if you look into the case, we have kind of done it step by step. So we have improved the efficiency by smaller investments that has happened several times each year. And I think in the Varberg case, we have kind of still to optimize the operations and so on.
14:38 We have bought a few bins to Varberg so we can have more stock.
14:48 I see your point, but it was just the 50 to 70 million. Given that you essentially had no capex in Q1, it's quite a steep step up in coming quarters then. But as I interpret it from your answers, you have no sort of planned capex investments involved. I'd rather continue to optimize existing infrastructure.
15:12 Not yet, but it might come.
15:16 Fair enough. Thank you so much for taking my questions.
15:19 Thank you. The next question comes from Benjamin Wallstedt from ABG Sundal Collier. Please go ahead.
15:33 Good morning, guys. I will go back to one of Johan's questions about the gross margin. I got the impression last conference call that while the campaign intensity was one issue you faced in Q4, the gross margin pressure you experienced was also an effect of purchasing to Varberg. I believe you, Johan, said that you were sort of still in the process of calibrating the purchases for the new logistics center, for example. In Q1, it appears Varberg purchasing is basically not an issue at all. Was this a quicker turnaround than you expected? or how should we think about this?
16:16 I mean, we have absolutely done much better purchasing in first quarter compared to fourth. I mean, I don't think it's probably too early to say that all problems is gone and to be sure about that, because if you have just one quarter, it's a little bit too early. But I mean, we have absolutely improved our purchasing process. and we will continue to improve it over time.
16:48 Perfect, thank you. Pär, you also write in the CEO letter about planning more investments to ramp up growth. Could you elaborate on the kind of investments you're referring to here? Or is this the apotea.no website, for example?
17:05 Zora mentioned that we have built a new e-commerce platform. I mean, it's not investment on... on the balance sheet, but it's working hours for the AI team and for the tech team. And then to improve the assortment, maybe do more marketing. So it can be a lot of different areas. Maybe not that big costs, but costs related to that. And we want to focus on growth and want to spend both money and time on on building more growth. So, because I think it's very valuable for both Apothea and for our shareholders.
17:53 Perfect. Thank you. That's clear. And sort of following on that then, you mentioned marketing spend and marketing investments as an example of such investments. While you don't share marketing ratios explicitly, could you give us a hint or an indication of whether or not your marketing ratio is sort of up or down compared to the time of the IPO, for example?
18:21 I think it's stable, quite stable. And I mean, our goal is to find profitable marketing and do that marketing. And if we I mean, for example, Google, if you it's not is not profitable to to buy such terms that is not profitable but we want to buy as much as we can that is profitable and so that's something that we continuously evaluate the marketing spend if we see that there's a room to increase the marketing in external channels that's the good return on investment that's something we
19:06 We do obviously, but I think as we've shared before, the main driver for Apothea's growth has always been having the best offering to the consumer and ensuring that with our attractive prices and speedy deliveries and free deliveries and attractive and large assortment that drives new customers, but also keeping the customers returning more frequently. And so that's the main of our focus, ensuring that the deliveries and the assortments are the right, et cetera.
19:42 I hope the customer is a good customer.
19:44 Yeah. And it might seem like, and that's, I think that's a good way to kind of drive growth. That's a long-term sustainable way of driving growth rather than having short-term adjustments in marketing, big calibration in marketing or prices, for example.
20:08 Thank you, that's very clear as well. Final one from me then. In essence, why do you not raise your short-term financial targets for the margin? I mean, you've showed in Q1 that you can deliver above 5% margins with the new setup running far from max or optimum capacity, I guess. One could assume that with further growth, you would scale more on the now higher DNA from Varber, for example, for a rather positive margin trajectory from here, assuming continued growth. So, yeah, you're above the 3-5% interval. Why keep it intact?
20:49 We mentioned just before the uncertainty in the world. I mean, we want to grow faster and want to spend money on that. And I think we need a few more quarters so I mean like fourth quarter was not that good so we need more time before we can say okay this is the new stable level where we can be because we don't want to over promise so that's why we
21:22 try to keep it that way and I mean we are in the middle of this short to mid-term corridor of being in within 85 percent we have a adjusted margin rolling 12 months of 4.2 percent so we are in the middle of that corridor and even though q4 was and I think we're fairly open that it was a q4 was a disappointment and low profitability below our expectations Q4 tend to be, with the seasonal variation and higher share of campaign sales, a softer profitable quarter compared to the other fake quarters during the year.
22:06 Perfect. Thank you. That's all I have for now. Thank you. The next question comes from Victor Hansen from DNB Carnegie. Please go ahead.
22:18 Good morning Per, Johan and Sara. A couple of questions from my side. I was curious on your impressions of the competitive environment during Q1 because we've had some peers commenting on this recently and it seems that the market remains tough, relatively low growth still. So what's your view on the competitive environment here?
22:43 I think the competitive environment is quite stable as well. We have had a very competitive market for several years and that's how we like it.
22:57 Okay, perfect. So nothing, no changes?
23:01 No, not really.
23:02 Okay. My next question is on your beauty segment. beauty products are up a lot. So do you have any comments on how growth was within this segment and how important you would say beauty is for you going forward to reach your sales targets?
23:26 It's an important segment and it is a broad segment as well, right? So it contains a lot of different type of products and it's going well. Good growth in that area. So it's one of the focus areas that we have. But I think in order to have a higher growth rate, we need to work on all categories.
23:48 Yeah, and we also have seasonal effects. I mean, now we are heading towards the summer and then you have like some protections that's a lot and in the autumn you have different products so all categories is very important for us and we want to grow all of them and we try to maximize the growth on all of them so we try to handle them individually and try to do as good as we can with everyone
24:15 I think in terms of the beauty segment in specific, we have done quite the large steps in terms of the assortment and so on. So we're very proud to welcome a lot of good brands to our site. And that's something we have been very proud of, I would say. So we're happy to see that the assortment is widening within those types of categories and especially in the more premium segment.
24:44 Perfect. And then on Varberg here, I was hoping that you could perhaps provide an estimate of the savings effects as you have lower fulfillment costs in Varberg compared to Morungova. And now you said you moved one third of your total orders.
25:04 Yes, I think it's still early days and I think we mentioned this before. Yes, we see a significant improved efficiency in Barber. However, it's early days in terms of ramping up and understanding the kind of what should I say, more steady state type of production costs in Varberg. And at the same time, we also are shifting the production between our sites and between different shifts. So it's at this point hard to say a fixed number, but yes, we see efficiencies in Varberg and we will come back to that. Absolutely.
25:50 Okay, perfect. And then a final question from my side. Yeah, the consumer sentiment, it's tough now with another war going on. How did April start?
26:06 We will need to come back to Q2 in the summer when we report the Q2 results. I think, yeah.
26:19 Fair enough. Thank you. Thank you very much.
26:26 Perfect. Thank you, everyone. That was the last question. Thank you for listening to the presentation of our quarterly report. And we wish you a pleasant day.
26:36 Thank you very much. Bye.
Follow Apotea AB into a list and get an email when it puts out news.
COO
CFO
CEO and Co‐founder
Analyst, SEB
Analyst, ABG Sundal Collier
Analyst, DNB Carnegie